In need of treatment? Merger control, pharmaceutical innovation, and consumer welfare

Journal of Legal Medicine

Volumn 21, Issue 3, 2000, Pages 271-349

  Ben Asher, Dror ^a  

^a HARVARD LAW SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPETITION; CONSUMER; DRUG INDUSTRY; LAW; LAW SUIT; MARKETING; PRESCRIPTION; REVIEW; WELFARE;

EID: 0033814110     PISSN: 01947648     EISSN: 1521057X     Source Type: Journal    
DOI: 10.1080/01947640050174813     Document Type: Article

References (103)

1. Sara Fisher Ellison, Book Review, 36 J. Econ. Lit. 1521 (1998) (reviewing Stuart O. Schweitzer, Pharmaceutical Economics and Policy (1997)).
2. William Lewis, M&A Activity Headsfor Record Book, Finan. Times, June 30, 1998 (the Financial Times is available at ).
3. F Allan Murray, Antitrust Isn’t Obsolete in an Era of High-Tech, Wall St. J., Nov. 10, 1997, at A-1;
4. George J. Alexander, Competing in Global Product Innovation: Is Antitrust Immunity Necessary ?, 6 Santa Clara Comp. & High Tech L.J. 147 (1991).
5. Richard Wolffe, Fed Chief Hits at Antitrust Officials, Finan. Times, June 17, 1998, at 1.
6. Bill Gates, Why the Justice Department Is Wrong, Wall St. J., Nov. 10, 1997, at A-22.
7. Andrew Ross Sorkin, Behind Biggest Drug Merger, Quest for a Research Pipeline, N.Y. Times, Jan. 18, 2000;
8. David Pilling et al., Astra andZeneca Confirm $35bn Deal, FiNAN.TiMES, Dec. 10, 1998; All Fall Down, supra note 2, at 65;
9. William Lewis et al., Zeneca and Astra Announce $67bn Merger, Finan. Times, Dec. 9, 1998;
10. Daniel Green, Merger Fever Returns to the Drugs Industry, Finan. Times, Jan. 21, 1998, at23, availablein 1998WL3526519;
11. Ron Winslow, Another Dose of Merger Mania May Be Headed for Drug Firms, Wall St. J., Jan. 21, 1998, at C1, available in 1998 WL-WSJ 3479663.
12. Mark D. Whitener, Competition and Antitrust Enforcement in the Changing Pharmaceutical Marketplace, 50 Food & Drug L.J. 301 (1995).
13. Roy Levy, The Pharmaceutical Industry: A Discussion of Competitive and Antitrust Issues in an Environment of Change, Bureau of Economics Staff Report, Federal Trade Commission (Mar. 1999).
14. Marting Gaynor & William B. Vogt, Antitrust and Competition in Health Care Markets, in Handbook of Health Economics (Anthony J. Culyer & Joseph P. Newhouse eds. forthcoming);
15. John J. Miles, Health Care & Antitrust Law: Principles and Practice (1992-98).
16. F.M. Scherer, Prices, Profits and Technological Progress inthePharmaceutical Industry 16-17 (Apr). 1993
17. Judy Foreman, Treating Impotence Getting Easier, Boston Globe, Apr. 20, 1998, at C1.
18. D. A. Siskind, Contributions of the Pharmaceutical Industry to Improved Health, in The Pharmaceutical Industry: Economics, Performance, and Government Regulation 41 (Cotton M. Lindsay ed. 1978).
19. F.M. Scherer, How USAntitrust Can GoAstray, 4 Int’l J. Econ. Business 239 (1997)
20. S. Lee, Global Pharmaceuticals: Winning Strategies in the Major Manufacturing Markets 7-9
21. Sharon Smith Holston, An Overview oflnternational Cooperation, 52Food & DrugL.J 197 (1997).
22. Ileana Dominguez-Urban, Harmonization inthe Regulation of Pharmaceutical Research and Human Rights: The Need to Think Globally, 30 Cornell Int’l L.J. 245 (1997).
23. Barry G. James, The Pharmaceutical Industry in 2000: Reinventing the Pharmaceutical Company 45 (The Economist Intelligence Unit, 1994);
24. Pisano, P., supra note 20, at 62-6
25. Daniel Green, Beyond the Barriers of Alchemy, Finan. Times, Dec. 16, 1995, section II, at 4.
26. Daniel Green, Biotechnology, Finan. Times Special Survey, Nov. 22, 1996, at 8 (Peptide Therapeutics & Medeva).
27. K.W. Clarkson, The Effects of Research and Promotion on Rates of Return, in Competitive Strategies in the Pharmaceutical Industry 255 (R.B. Helmes ed. 1996)
28. Clive Cookson, Cautionary TaleforOptimists, Finan. Times, Oct.31,1996, at 12. SeealsoImmunex Trial Data is Positive for Enbrel, Arthritis Treatment, Wall St. J., Nov. 10, 1997, at A-4.
29. Peter Barton Hutt, The Legal Requirement that Drugs Be Proved Safe and Effective Before Their Use, in Controversies in Therapeutics 495 (Louis Lasagna ed. 1980).
30. Laurie McGinley, Pharmaceuticals: Clinton Wants Drug-Safety Tests for Children, Wall St. J., Aug. 13, 1997, at B1, available in 1997 WL-WSJ 2431346.
31. Victoria Griffith, Orphan’s Home, Finan. Times, Nov. 22, 1996.
32. John Leland, A Pill for Impotence, Newsweek, Nov. 17, 1997, at 64.
33. Joseph D. Jackson, Pricing and Perspectives, in Studies in Pharmaceutical Economics 359, 368
34. Julian H. Shelley, The Ocean and the Bucket, in Success and Creativity, supra note 14, at 13.
35. Gregory J. Werden, Demand Elasticities inAntitrustAnalysis, 66 Antitrust L.J. 363 (1998). Onconsumers and the nature of demand for pharmaceuticals, see Schweitzer, supra note 27, § II.
36. Daniel Vasella, Catalyst for Top-down Change, Finan. Times, Feb. 10, 1997
37. Derek C. Bok, Section 7 of the Clayton Act and the Merging of Law and Economics, 74 Harv. L. Rev. 226, 307, 318 (1960)
38. Herbert Hovenkamp, Economics and Federal Antitrust Law (1985)
39. Thomas N. Dahdouh & James F. Mongoven, The Shape of Things to Come: Innovation Market Analysis in Merger Cases, 64
40. Antitrust L.J. 405 (1995). On the Horizontal Merger Guidelines and market definition
41. Alan J. Cox, Antitrust and Intellectual Property Market Definition, 483 PLI/Pat 131 (Practising Law Institute, 1997)
42. David S. Evans, Market Definition in Antitrust and Patent-Infringement Litigation, 414 PLI/Pat 595 (Practising Law Institute, 1995).
43. Roger Lowenstein, From Sherman to Pitofsky, Wall St. J., Feb. 27, 199
44. Richard J. Gilbert & Steven C. Sunshine, Incorporating Dynamic Efficiency Concerns in Merger Analysis: The Use ofInnovation Markets, 64 Antitrust L.J. 569, 594 (1995).
45. Ronald Alsop, Splitting the Headache Market, Drug Firms Create a Big Niche in Migraines, WALL ST. J., Jan. 22, 1998, at A1, available in 1998 WL-WSJ 3479981.
46. Richard Dunford, The Suppression of Technology as a Strategy for Controlling Resource Dependence, 32 Admin. Sci. Q. 512, 513 (1987).
47. David T. Scheffman, Making Sense of Mergers, 38 Antitrust 715, 724 (1993).
48. James B. Kobak, Jr. & Richard P. McGuire, FTC Looks at Merger's Antitrust Effects on R&D: Agency Alleges that a Merger Would Reduce Competition to Develop Future Drug Products, 19 Nat’l L.J. C3 (Mar. 31, 1997).
49. Sumanth Addanki, The DOJ’s Draft Intellectual Property Guidelines: An Economist's First Look, 4 Euro. Competition L. Rev. 220 (1995);
50. Andrew C. Hruska, A Broad Market Approach to Antitrust Product Market Definition in Innovative Industries, 102 Yale L.J. 305 (1992).
51. Lawrence B. Landman, Did Congress Actually Create Innovation Markets?, 13 Berkeley Tech. L.J. 721 (1998)
52. Nicholas A. Widenell, The Crystal BallofInnovation Market Analysis in Merger Review: An Appropriate Means of Predicting the Future?, 4 Geo. Mason L. Rev. 369 (1996)
53. James B. Kobak, Jr., Running the Gauntlet: Antitrust and Intellectual Property Pitfalls on the Two Sides of the Atlantic, 64 Antitrust L.J. 341, 361-62 (1996).
54. Bill Bishop & Cristina Caffarra, Dynamic Competition and Aftermarkets, 19 Euro. Competition L. Rev. 265, 266 (1998)
55. Richard J. Urowsky et al., Market Definition and “Standards,” available in 1996 WL CA26 ALI-ABA 19 (Jan. 25, 1996)
56. F. M. Scherer & D. Ross, Industrial Market Structure and Economic Performance 418 (2d ed. 1980).
57. F. M. Scherer, Innovation and Small Firms, Testimony Before the Subcommittee on Monopolies and Commercial Law, Committee on the Judiciary, United States House of Representatives, Feb. 24, 1988, at 4-5
58. Michael E. Porter, The Competitive Advantage of Nations 49 (1990)
59. F.M. Scherer, Does Antitrust Compromise Technological Efficiency?, 15 Eastern Econ. J. 1, 2 (1989)
60. Donald L. Alexander, R&D Productivity and Global Market Share in the Pharmaceutical Industry, in Competitive Strategies, supra note 38, at 130-51.
61. M.J. Crumpton, Research Outside Industry-The Contrasts, in Succes
62. William C. Bogner & Howard Thomas, Drugs to Market: Creating Value and Advantage in the Pharmaceutical Industry 20(1996).
63. A. Reyntjens & S. Van Reet, Success Factors of Janssen Research, in Success, supra note 14, at 5
64. Henry G. Grabowski & John M. Vernon, Pioneers, Imitators, and Generics, 102 Q.J. Econ. 491 (1987).
65. Jerome E. Schnee & Erol Caglarcan, Economic Structure and Performance of the Ethical Pharmaceutical Industry, in Pharmaceutical Industry, supra note 17, at 32.
66. Henri G. Grabowski, The Determinants of Industrial Research and Development: A Study of the Chemical, Drug, and Petroleum Industries, J. Politic. Econ. 292 (Mar.-Apr. 1963).
67. Stephen S. Hall, Success Is Like a Drug, N.Y. Times Mag., Nov. 23, 199
68. Lawrence M. Fisher, Drug Makers at Thresholds of a New Therapy, N.Y. Times, Jan. 17, 1998, at B1.
69. Michael Waldholz, Glaxo, Roche Race to Market a New Flu Drug, Wall St. J., Oct. 2, 1997, at B7, available in 1997 WL-WSJ 14168502.
70. Lynne G. Zucker & Michael R. Darby, Costly Information in Firm Transformation, Exit, or Iain Cockburn & Rebecca Henderson, Public-Private Interaction in Pharmaceutical Research (National Bureau ofEconomic Research, Sept. 1995).
71. Azam H. Aziz, Defining Technology and Innovation Markets: The DOJ' Antitrust Guidelines for the Licensing of Intellectual Property, 24 Hofstra L. Rev. 475, 507-10 (1995).
72. Mauritz Dolmans, Restrictions on Innovation: An EU Antitrust Approach, 66 AntitrustL.J. 455 (1998).
73. A. L. Drasdo, Mergersand Takeovers Challenge thePharmaceuticalIndustry in the UK, 14 C.M.R. News 1 (1996).
74. Daniel Green, Tonic for Drug Companies, Finan. Times, Jan. 7, 1997, at 4;
75. Bethan Hutton, Consolidation Prescribed, FINAN. TIMES, Apr. 24, 1997. But see Canadian Agency, supra note 210.
76. Stephen D. Moore, Novartis Considers How to Make a Giant Even Bigger, Wall St. J., Aug. 29, 1997
77. C. V. Hall & H. M. Strimpel, Mergers and Acquistitions within the Biotechnology Industry, in The Business of Biotechnology: From the Bench to the Street 273 (Richard D. Ono ed. 1991).
78. John Wilman, Do Mergers Help Consumers ?, Finan. Times, July 23, 1998, at 25.
79. Jeremy Lever, GlaxoSmithKline Deal Raises Specialist Labour Concerns, Letters to the Editor, Finan. Times, Feb. 4, 1998
80. Robert Pear, Medical Research to Get More Money from Government, N.Y. Times, Jan. 3, 1998.
81. Joseph Kattan, The Role of Efficiency Considerations in the Federal Trade Commission’s Antitrust Analysis, 64 Antitrust L.J. 613, 618-19 (1996).
82. Virginia Marsh, Shield: Biotech Company PlansAxis Takeover, Finan. Times, Jan. 19, 1999.
83. Dennis A. Yao & Susan S. DeSanti, Innovation Issues Under the1992 Merger Guidelines, 61 Antitrust L.J. 505,513 (1993).
84. Daniel Green, Merger Fever Returns to the Drug Industry, Finan. Times, Jan. 21, 1998, at 23, available in 1998 WL 3526519.
85. Daniel Green et al., SmithKline-Glaxo GBP 100bn Merger Plan, Finan. Times, Jan. 31, 1998, at 1.
86. Victoria Griffith, Switched-on Defences, Finan. Times, Oct. 10, 1996, at 20
87. Peter S. Arno et al., Rare Diseases, Drug Development, and AIDS: The Impact ofthe Orphan Drug Act, 72 Milbank Q. 231 (1995).
88. Robert H. Blank, The Price of Life: The Future of American Health Care 155 (1997).
89. Thomas M. Jorde & David J. Teece, Competing Through Innovation: Implications for Market Definitions, 64 Chicago-KentL. Rev. 741 (1988).
90. Matt Villano, The Word on Clinical Trials, Boston Globe, June 1, 1998
91. Joseph Kattan, Antitrust Considerations in Innovation-Driven Markets, 21 Can.-U.S. L.J. 115, 118-19 (1995)
92. Virgina Marsh, Peptide: PMC Stake and Extends Alliance, Finan. Times, Jan. 30, 1999.
93. Victoria Griffith, Ariad: Anaemia Therapy Lifts Drugs Firm, Finan. Times, Jan. 5, 1998.
94. Jonathan M. Jacobson & Tracy Greer, Twenty-One Years of Antitrust Injury: Down the Alley with Brunswickv. PuebloBowl-O-Mat, 66 Antitrust L.J. 273 (1998)
95. Robert A. Freeman & Rachel F. Tasch, The Technology Trust Fund: Paying for Medical Technology, in Studies, supra note 51, at 40
96. Laurie McGinley, Clinton to Order Patients’ Rights Be Part of Federal Health Plans, Wall St. J., Feb. 20, 1998
97. Eleanor M. Fox, Mergers ‘R Us: Has Antitrust Gone the Way of the 5 & 10?, Wash. Post, Mar. 30.
98. Bryan R. Luce & Anne Elixhauser, Socio economic Evaluation and Health Care Industry, in Studies, supra note 51.
99. Peter J. Neumann et al., The FDA and Regulation of Cost-Effectiveness Claims, 15 Health Aff. 54 (Fall 1996).
100. Howard J. Beales III, New UsesforOldDrugs, in Competitive Strategies, supra note 38, at 281;
101. John E. Calfee, The Leverage Principle in the FDA' Regulation of Information, in Competitive Strategies, supra note 38, at 306;
102. Ronald W. Hansen, Cost and Benefits of Cost-Benefit Analysis in Pharmaceutical Promotion and Utilization Decisions, in Competitive Strategies, supra note38, at 322;
103. William C. Macleod et al., Commentary on Part Four, in Competitive Strategies, supra note 38, at 37.